drugset / Trial / NCT01431170
Safety and Efficacy Study of Besivance™ for Treatment of Congenital Nasolacrimal Duct Obstruction in Children
Phase 1
Completed
24 enrolled
Rutgers, The State University of New Jersey
Bausch & Lomb Incorporated · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The goal of the study is to evaluate the application of Besivance™ (besifloxacin ophthalmic suspension, 0.6%) to treat congenital nasolacrimal duct obstruction in children. The hypothesis of the study is that Besivance™ is as safe and effective as the current standard of care for the treatment of nasolacrimal duct obstruction in children.
Timeline
- Start
- 2011-09
- Primary completion
- 2014-06
- Completion
- 2014-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Besifloxacin | Small molecule | 0.6 % | Other |
| Comparator | Polytrim | Unknown | — | Other |